Philip Jermann

885 total citations
19 papers, 372 citations indexed

About

Philip Jermann is a scholar working on Cancer Research, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Philip Jermann has authored 19 papers receiving a total of 372 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Cancer Research, 10 papers in Oncology and 9 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Philip Jermann's work include Cancer Genomics and Diagnostics (13 papers), Lung Cancer Treatments and Mutations (9 papers) and Cancer Immunotherapy and Biomarkers (7 papers). Philip Jermann is often cited by papers focused on Cancer Genomics and Diagnostics (13 papers), Lung Cancer Treatments and Mutations (9 papers) and Cancer Immunotherapy and Biomarkers (7 papers). Philip Jermann collaborates with scholars based in Switzerland, Italy and United States. Philip Jermann's co-authors include Dirk Schübeler, Lukas Burger, Leslie Hoerner, Ilaria Alborelli, Luca Quagliata, Lukas Bubendorf, Katharina Leonards, Markus Tolnay, Spasenija Savic Prince and Sacha I. Rothschild and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Philip Jermann

17 papers receiving 368 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Philip Jermann Switzerland	8	187	165	128	111	40	19	372
Sebastian Uhrig Germany	7	162 0.9×	101 0.6×	115 0.9×	65 0.6×	63 1.6×	17	360
Karen Cravero United States	10	119 0.6×	141 0.9×	94 0.7×	60 0.5×	55 1.4×	20	281
Erica Marchlik United States	3	101 0.5×	83 0.5×	145 1.1×	103 0.9×	42 1.1×	7	295
Mohamed Kabbout United States	9	242 1.3×	126 0.8×	82 0.6×	128 1.2×	22 0.6×	11	353
Maxim Ivanov Russia	8	151 0.8×	184 1.1×	88 0.7×	71 0.6×	59 1.5×	24	302
Xinkai Cao China	8	194 1.0×	233 1.4×	85 0.7×	71 0.6×	42 1.1×	10	376
Laura Arthur United Kingdom	9	102 0.5×	139 0.8×	153 1.2×	74 0.7×	44 1.1×	21	271
Suenori Chiku Japan	10	336 1.8×	163 1.0×	131 1.0×	122 1.1×	41 1.0×	11	483
Gregory McCarty United States	10	309 1.7×	130 0.8×	81 0.6×	129 1.2×	20 0.5×	12	416
Hirohiko Totsuka Japan	8	195 1.0×	87 0.5×	133 1.0×	98 0.9×	35 0.9×	11	317

Countries citing papers authored by Philip Jermann

Since Specialization

Citations

This map shows the geographic impact of Philip Jermann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philip Jermann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philip Jermann more than expected).

Fields of papers citing papers by Philip Jermann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philip Jermann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philip Jermann. The network helps show where Philip Jermann may publish in the future.

Co-authorship network of co-authors of Philip Jermann

This figure shows the co-authorship network connecting the top 25 collaborators of Philip Jermann. A scholar is included among the top collaborators of Philip Jermann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philip Jermann. Philip Jermann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Alborelli, Ilaria, Melanie Demes, Peter J. Wild, et al.. (2025). ERBB2 Mutation Testing in NSCLC: A Pan-European Real-World Evaluation of the Oncomine Precision Assay. SHILAP Revista de lepidopterología. 6(3). 19–19.

Normanno, Nicola, José Carlos Machado, Edoardo Pescarmona, et al.. (2023). European Real-World Assessment of the Clinical Validity of a CE-IVD Panel for Ultra-Fast Next-Generation Sequencing in Solid Tumors. International Journal of Molecular Sciences. 24(18). 13788–13788. 2 indexed citations

Hetzel, Jürgen, Laetitia Mauti, Philip Jermann, et al.. (2023). Only EBUS-Guided Mediastinal Lymph Node Cryobiopsy Enabled Immunotherapy in a Patient with Non-Small Cell Lung Cancer. Journal of Clinical Medicine. 12(6). 2355–2355. 2 indexed citations

Alborelli, Ilaria, Mathias Gugger, Philip Jermann, et al.. (2022). Prevalence of Molecular Alterations in a Swiss Cohort of 512 Colorectal Carcinoma Patients by Targeted Next-Generation Sequencing Analysis in Routine Diagnostics. Pathobiology. 90(3). 166–175. 3 indexed citations

Addeo, Alfredo, Sacha I. Rothschild, Martina Schneider, et al.. (2022). Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II study. Lung Cancer. 172. 154–159. 13 indexed citations

Alborelli, Ilaria & Philip Jermann. (2022). Preanalytical Variables and Sample Quality Control for Clinical Variant Analysis. Methods in molecular biology. 2493. 331–351. 1 indexed citations

Hench, Juergen, Colm J. O’Rourke, Nathalie Meyer‐Schaller, et al.. (2022). Genetic and epigenetic analysis of hepatocellular adenomas with atypical morphological features. Histopathology. 82(5). 722–730. 2 indexed citations

Flanagan, Kevin C., Jeffrey Hiken, Jon R. Armstrong, et al.. (2022). T cell subtype profiling measures exhaustion and predicts anti-PD-1 response. Scientific Reports. 12(1). 1342–1342. 9 indexed citations

Medinger, Michael, Dominik Heim, Alexandar Tzankov, et al.. (2022). CB‐103: A novel CSL‐NICD inhibitor for the treatment of NOTCH‐driven T‐cell acute lymphoblastic leukemia: A case report of complete clinical response in a patient with relapsed and refractory T‐ALL. SHILAP Revista de lepidopterología. 3(3). 1009–1012. 13 indexed citations

10.

Alborelli, Ilaria, Katharina Leonards, E. Keller, et al.. (2021). MA09.02 SAKK 16/14 - T-Cell Receptor Repertoire Metrics Predict Response to Neoadjuvant Durvalumab in Patients With Stage IIIA(N2) NSCLC. Journal of Thoracic Oncology. 16(10). S911–S911. 3 indexed citations

11.

Alborelli, Ilaria, Obinna Chijioke, Spasenija Savic Prince, et al.. (2020). Robust assessment of tumor mutational burden in cytological specimens from lung cancer patients. Lung Cancer. 149. 84–89. 17 indexed citations

12.

Alborelli, Ilaria, Daniele Generali, Philip Jermann, et al.. (2019). Cell-free DNA analysis in healthy individuals by next-generation sequencing: a proof of concept and technical validation study. Cell Death and Disease. 10(7). 534–534. 100 indexed citations

13.

Garofoli, Andrea, Hesam Montazeri, Philip Jermann, et al.. (2019). PipeIT. Journal of Molecular Diagnostics. 21(5). 884–894. 10 indexed citations

14.

Hench, Jürgen, et al.. (2019). Aktuelle molekularpathologische Methoden. Therapeutische Umschau. 76(4). 173–178. 1 indexed citations

15.

Rothschild, Sacha I., Ilaria Alborelli, Katharina Leonards, et al.. (2019). Tumor mutational burden assessed by a targeted NGS assay to predict clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.. Journal of Clinical Oncology. 37(15_suppl). e14266–e14266. 1 indexed citations

16.

Jermann, Philip, Katharina Leonards, Timothy J. Looney, et al.. (2019). TCR-beta repertoire convergence and evenness are associated with response to immune checkpoint inhibitors. Annals of Oncology. 30. v851–v851. 1 indexed citations

17.

Alborelli, Ilaria, Katharina Leonards, Sacha I. Rothschild, et al.. (2019). Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non‐small cell lung cancer. The Journal of Pathology. 250(1). 19–29. 84 indexed citations

18.

Rothschild, Sacha I., Philip Jermann, Spasenija Savic, et al.. (2018). Tumor mutational burden assessed by a targeted NGS assay to predict benefit from immune checkpoint inhibitors in non-small cell lung cancer.. Journal of Clinical Oncology. 36(15_suppl). e15075–e15075. 1 indexed citations

19.

Jermann, Philip, Leslie Hoerner, Lukas Burger, & Dirk Schübeler. (2014). Short sequences can efficiently recruit histone H3 lysine 27 trimethylation in the absence of enhancer activity and DNA methylation. Proceedings of the National Academy of Sciences. 111(33). E3415–21. 109 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact